[Meningococcal serogroup B vaccines].
Centre Hospitalier de Versailles, 177, rue de Versailles, 78150 Le Chesnay, France.Archives de Pédiatrie (Impact Factor: 0.41). 09/2012; 19 Suppl 2:S65-9.
The diversity and antigenic variability of Neisseria meningitidis serogroup B strains around the world has been a major challenge to developing a vaccine with broad coverage. Outer-membrane vesicle vaccines appear to be safe and effective but are strain-specific vaccines and used in delimited areas. Also, recombinant protein vaccines such as factor H binding protein, given alone or in combination with others antigens have been developed and may be effective against the majority of group B strains.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.